Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas
Phase of Trial: Phase I
Latest Information Update: 23 Aug 2018
Price : $35 *
At a glance
- Drugs ADU 623 (Primary)
- Indications Astrocytoma
- Focus Adverse reactions; First in man
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.
- 22 Sep 2017 Status changed from recruiting to active, no longer recruiting.